Refine by
Human Cancer Articles & Analysis
30 news found
Health regulatory authorities consider this new bacterial reverse mutation test to be the gold standard for predicting a substance's potential to cause cancer in humans. It is highly sensitive and can detect suitable mutants in a wide range of bacteria. ...
BySTEMart
This versatile technology for automated data analysis facilitates retrospective and prospective human tissue studies. It is a practical and effective tool for high-throughput molecular analysis of tissues, helping to identify new diagnostic and prognostic markers and targets for human cancers, with a wide range of potential applications in basic ...
“The 52.4% ORR from the TORCH-2 study with ATG-008 and toripalimab in patients with relapsed/metastatic cervical cancer, coupled with a manageable safety profile, is an exciting result that provides a potential guide to a registration program for ATG-008. ...
The ISET® patented EC-marked platform is able to extract down to one single cancer cell of any type from 10 ml of blood, thus a tumor cell mixed with 100 million leukocytes and 50 billion erythrocytes, according to peer-reviewed published studies. ...
This data will be made available to other researchers who may find it useful for their cancer research as well as other applications.” Dr. Jennifer Willcox, PI of the UC Davis VACCS trial site noticed how many owners had interest in the potential human implications for the trial. “One remarkable experience for me was how many of the owners were ...
ByCalviri
Although immunotherapy is a true breakthrough in cancer treatment and is now approved for use in more than 20 different human cancers, most patients unfortunately do not respond. If pharmacologic inhibition of PP2A significantly enhances immunotherapy of even a few human cancers, it will be a game-changer. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus ...
Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced it has hired David Green as its Chief Executive Officer and appointed Mr. ...
(Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. ...
” About Virometix Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, ...
About Virometix Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including ...
Wandell added, we have made significant progress in systems development so the investigational treatment of humans with pancreatic cancer is the next milestone on the path toward commercialization. ...
Damadian, M.D., founder and chairman of FONAR Corporation, first thought about developing a device using magnetic resonance to scan the human body to detect cancer. On September 17, 1969, Dr. Damadian sent a letter to Dr. ...
About Biosceptre:Biosceptre is a Cambridge, UK headquartered biotechnology company focused on developing next generation cancer treatments targeting nfP2X7. Sir Greg Winter, founder of Cambridge Antibody Technology and Domantis is acting chairman of the Biosceptre Board of Directors and also chairs the Science Advisory Board. Biosceptre’s clinical programs include systemic ...
Biosceptres’ clinical candidates specifically target a non-functional form of the P2X7 ion channel that is present only on the surface of cancer cells. Each of these clinical candidates has shown promising signs of efficacy in pre-clinical development as well as indicative efficacy and safety in compassionate access patients. ...
Health effects may include: · Eye, nose and throat irritation · Headaches, loss of coordination and nausea · Damage to liver, kidney and central nervous system · Some of these chemicals can cause cancer in animals and some are suspected or known to cause cancer in humans Key signs ...
Scientists can now gain a greater understanding of redox biology-the study of electron flow through biological circuits, sensors, and switches-applicable in many areas critical to human health, including cancer, heart disease, aging, cardiovascular disease and obesity. ...
The scientists previously found that APOBEC enzymes were responsible for a substantial number of mutations in 80-90 percent of bladder and cervical cancers, and 20-30 percent of head and neck, breast, and lung cancers. ...